X0609 4 2026-10-15 0001438533 Travere Therapeutics, Inc. TVTX 0001763494 Dube Eric M false C/O TRAVERE THERAPEUTICS, INC. 3611 VALLEY CENTRE DR., SUITE 300 SAN DIEGO CA 92130 true true false false CHIEF EXECUTIVE OFFICER 1 Common Stock 2026-10-15 4 M 0 43735 26.88 A 476621 D Common Stock 2026-10-15 4 M 0 200000 8.93 A 676621 D Common Stock 2026-10-15 4 S 0 128065 52.9672 D 548556 D Common Stock 2026-10-15 4 S 0 37270 54.1997 D 511286 D Common Stock 2026-10-15 4 S 0 78400 55.0179 D 432886 D Employee stock option (right to buy) 26.88 2026-10-15 4 M 0 43735 0 D 2031-01-21 Common Stock 43735 168925 D Employee stock option (right to buy) 8.93 2026-10-15 4 M 0 200000 0 D 2034-01-31 Common Stock 200000 160000 D This sale was made pursuant to a written plan adopted on June 16, 2026, meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended. The weighted average sale price for the transaction reported was $52.9672, and the range of prices were between $52.63 and $53.6250. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each price will be provided. The weighted average sale price for the transaction reported was $54.1997, and the range of prices were between $53.63 and $54.62. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each price will be provided. The weighted average sale price for the transaction reported was $55.0179, and the range of prices were between $54.63 and $55.57. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each price will be provided. The stock option is fully vested and exercisable. One-fourth of the shares subject to the stock option vested and became exercisable on January 31, 2025, and the remaining shares vest in 36 equal monthly installments thereafter. /s/ Elizabeth E. Reed, Attorney-in-Fact 2026-10-19